| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Pathology,*
Ludwig Maximilians
University of Munich, 80337 München, and the Department of
Virology,
Max Planck Institute for
Biochemistry, 82152 Martinsried, Federal Republic of Germany
The endothelium is one of the largest cellular compartments of the human body and has a high proliferative potential. However, angiosarcomas are among the rarest malignancies. Despite this interesting contradiction, data on growth and angiogenesis control mechanisms of angiosarcomas are scarce. In this study of 19 angiosarcomas and 10 benign vascular control lesions we investigated the sequence and expression of the p53 tumor suppressor gene and the expression of the mdm-2 proto-oncogene, which is a negative regulator of p53 activity and of the vascular endothelial growth factor (VEGF), whose expression, among other factors, is regulated by the p53/MDM-2 pathway. Ten sarcomas (53%) exibited clear nuclear p53 protein accumulation. Two of these cases revealed mutations in the sequence-specific DNA binding domain of the p53 gene. Thirteen angiosarcomas (68%) showed an increased amount of MDM-2 protein. Elevated expression of p53 and MDM-2 protein correlated with increased VEGF expression, which was found in nearly 80% of the angiosarcoma cases. Negative or clearly lower immunostaining was obtained in cases from the benign control collective. Only one case of a juvenile hemangioma reached the cutoff value of p53 positivity coincidentally with high VEGF expression. Our data suggest that the p53/MDM-2 pathway is impaired in about two-thirds (14/19) of the angiosarcomas. This may be a key event in the pathogenesis of human angiosarcomas. The increased VEGF expression observed supports this hypothesis.
This article has been cited by other articles:
 |
|
 |
|
  J.-C. M. Walkes, W. R. Smythe, and M. J. Reardon Cardiac Neoplasms Card. Surg. Adult, January 1, 2008; 3(2008): 1479 - 1510. [Full Text]
|
|
|
|
 |
|
 F Noack, L Balleisen, P Valent, and H-P Horny Angiosarcoma of bone marrow with unusual expression of chymase: diagnosis in a trephine biopsy specimen J. Clin. Pathol., October 1, 2007; 60(10): 1183 - 1183. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Zhou, Y. Zhai, Y. Cui, X. Zhang, X. Dong, H. Yang, Y. He, K. Yao, H. Zhang, L. Zhi, et al. MDM2 Promoter SNP309 Is Associated with Risk of Occurrence and Advanced Lymph Node Metastasis of Nasopharyngeal Carcinoma in Chinese Population Clin. Cancer Res., May 1, 2007; 13(9): 2627 - 2633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Perry, J. Banyard, E. R. McLaughlin, R. Watnick, A. Sohn, D. N. Brindley, T. Obata, L. C. Cantley, C. Cohen, and J. L. Arbiser AKT1 Overexpression in Endothelial Cells Leads to the Development of Cutaneous Vascular Malformations In Vivo Arch Dermatol, April 1, 2007; 143(4): 504 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. LaRusch, M. W. Jackson, J. D. Dunbar, R. S. Warren, D. B. Donner, and L. D. Mayo Nutlin3 Blocks Vascular Endothelial Growth Factor Induction by Preventing the Interaction between Hypoxia Inducible Factor 1{alpha} and Hdm2 Cancer Res., January 15, 2007; 67(2): 450 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Yang, C. S. Zong, W. Xia, Y. Wei, M. Ali-Seyed, Z. Li, K. Broglio, D. A. Berry, and M.-C. Hung MDM2 Promotes Cell Motility and Invasiveness by Regulating E-Cadherin Degradation. Mol. Cell. Biol., October 1, 2006; 26(19): 7269 - 7282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kaluzova, S. Kaluz, M. I. Lerman, and E. J. Stanbridge DNA Damage Is a Prerequisite for p53-Mediated Proteasomal Degradation of HIF-1{alpha} in Hypoxic Cells and Downregulation of the Hypoxia Marker Carbonic Anhydrase IX Mol. Cell. Biol., July 1, 2004; 24(13): 5757 - 5766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Reardon and W. R. Smythe Cardiac Neoplasms Card. Surg. Adult, January 1, 2003; 2(2003): 1373 - 1400. [Full Text]
|
|
|
|
|
|
M. G. Backlund, S. L. Trasti, D. C. Backlund, V. L. Cressman, V. Godfrey, and B. H. Koller Impact of Ionizing Radiation and Genetic Background on Mammary Tumorigenesis in p53-deficient Mice Cancer Res., September 1, 2001; 61(17): 6577 - 6582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zietz, U. Rumpler, M. Sturzl, and U. Lohrs Inverse Relation of Fas-Ligand and Tumor-Infiltrating Lymphocytes in Angiosarcoma : Indications of Apoptotic Tumor Counterattack Am. J. Pathol., September 1, 2001; 159(3): 963 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Linderholm, T. Lindahl, L. Holmberg, S. Klaar, J. Lennerstrand, R. Henriksson, and J. Bergh The Expression of Vascular Endothelial Growth Factor Correlates with Mutant p53 and Poor Prognosis in Human Breast Cancer Cancer Res., March 1, 2001; 61(5): 2256 - 2260. [Abstract] [Full Text]
|
|
|
|
|
|
L. Zhang, D. Yu, M. Hu, S. Xiong, A. Lang, L. M. Ellis, and R. E. Pollock Wild-Type p53 Suppresses Angiogenesis in Human Leiomyosarcoma and Synovial Sarcoma by Transcriptional Suppression of Vascular Endothelial Growth Factor Expression Cancer Res., July 1, 2000; 60(13): 3655 - 3661. [Abstract] [Full Text]
|
|
|
|
|
|
J. L. Arbiser, H. Larsson, L. Claesson-Welsh, X. Bai, K. LaMontagne, S. W. Weiss, S. Soker, E. Flynn, and L. F. Brown Overexpression of VEGF 121 in Immortalized Endothelial Cells Causes Conversion to Slowly Growing Angiosarcoma and High Level Expression of the VEGF Receptors VEGFR-1 and VEGFR-2 in Vivo Am. J. Pathol., April 1, 2000; 156(4): 1469 - 1476. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
